Physician profile
Wei Lin
NPI 1386621654
$8,541.61
in general payments reported to CMS, 2019-2025
26 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,828 · 2020: $2,847 · 2021: $249 · 2022: $1,102 · 2023: $200 · 2024: $98.95 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665 · Consulting Fee: $650 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.81 |
| Consulting Fee | $650.00 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $2,800.00 | 2020 | |
| Amgen INC. | $2,551.86 | 2019 | |
| Daiichi Sankyo INC. | $900.59 | 2022-2025 | Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $391.26 | 2022-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $171.33 | 2022-2025 | Datroway |
| Eisai INC. | $152.86 | 2022 | |
| Genentech USA, INC. | $151.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $136.53 | 2020-2021 | |
| Seagen INC. | $132.08 | 2022 | |
| Agios Pharmaceuticals, INC. | $128.99 | 2019 | |
| Tg Therapeutics, INC. | $124.99 | 2021 | |
| Iovance Biotherapeutics, INC. | $121.24 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $118.31 | 2022 | |
| Abbvie INC. | $112.42 | 2020-2025 | |
| Genmab U.S., INC. | $98.95 | 2024 | Epkinly |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $90.48 | 2025 | Rybrevant, Carvykti |
| Morphosys, US INC. | $90.43 | 2022 | |
| Astellas Pharma US INC | $82.03 | 2020-2022 | |
| Pfizer INC. | $45.39 | 2019-2022 | |
| Gilead Sciences, INC. | $36.86 | 2022 | |
| Exelixis INC. | $22.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2022 | |
| Glaxosmithkline, LLC. | $16.87 | 2022 | |
| Kyowa Kirin, INC. | $16.29 | 2022 | |
| Array Biopharma INC | $15.90 | 2022 | |
| Caris Mpi, INC. | $14.87 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.